Quantcast

Latest Anticonvulsants Stories

2014-08-07 15:44:44

The JAMA Network Journals Researchers have identified genetic variants that are associated with severe adverse skin reactions to the antiepileptic drug phenytoin, according to a study in the August 6 issue of JAMA. Phenytoin is a widely prescribed antiepileptic drug and remains the most frequently used first-line antiepileptic drug in hospitalized patients. Although effective for treating neurological diseases, phenytoin can cause cutaneous (skin) adverse reactions ranging from mild to...

2014-07-28 08:30:11

An Innovative Approach That Puts Clinicians in Charge MAPLE GROVE, Minn., July 28, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that it has launched the Upsher-Smith Galaxy(TM), a new and growing suite of antiepileptic drugs (AEDs) that offers people with epilepsy consistent, affordable and accessible therapies. The current Upsher-Smith Galaxy(TM) Portfolio includes seven frequently prescribed AEDs which represent more than one out of every three...

2014-07-25 23:01:34

On July 21, the FDA informed that one lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by American Health Packaging (AHP), are recalled due to mislabeled packaging. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) July 25, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Ibuprofen and Oxcarbazepine...

2014-07-23 08:31:01

- Brivaracetam is the newest investigational medicine to emerge from UCB's rich late-stage pipeline BRUSSELS, July 23, 2014 /PRNewswire/ -- regulated information -- UCB today announced an important advance in its research and development pipeline with positive topline results from the latest Phase 3 study with brivaracetam. This study was designed to evaluate the efficacy and safety of brivaracetam (100 and 200 mg/day, without titration) compared to placebo, as adjunctive treatment in adult...

2014-07-18 23:01:32

Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/epilepsy-therapeutics-market.html. (PRWEB) July 18, 2014 Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends...

2014-07-15 16:27:31

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patternshttps://www.reportbuyer.com/product/2052297/Epilepsy-Therapeutics-in-Major-Developed-Markets-to-2019---New-AEDs-with-Novel-Mechanisms-of-Action-Signal-a-Shift-in-Treatment-Patterns.htmlEpilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with...

2014-07-14 08:27:51

Authorized Generic Topiramate Extended-Release Capsules Available Nationwide MAPLE GROVE, Minn., July 14, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced the launch of Topiramate Extended-Release Capsules, the authorized generic of the recently Food and Drug Administration (FDA) approved Qudexy(TM) XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK)...

2014-07-11 08:24:53

MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada approved APTIOM(TM) (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy. APTIOM(TM) is not indicated for use in patients under 18 years of age. Epilepsy is one of the most common neurological disorders and...

2014-06-30 12:26:21

LONDON, June 30, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Seizures - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/seizures_pipeline_review_h1_2013.html Seizures - Pipeline Review, H1 2014 SummaryGlobal Markets Direct's, 'Seizures - Pipeline Review, H1 2014', provides an overview of the Seizures's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Seizures,...

2014-06-30 08:31:21

First Branded Product in CNS Portfolio Now Available MAPLE GROVE, Minn., June 30, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced that Qudexy(TM) XR (topiramate) extended-release capsules is now available to patients in the United States. Qudexy(TM) XR is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK) profile. It was approved by the U.S. Food and Drug Administration in March 2014...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related